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Abstract
Background: Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates.
Methodology/Principal Findings: We demonstrate that the VSVDG/ZEBOVGP vaccine given 28 days pre-challenge either
intranasally (IN), orally (OR), or intramuscularly (IM) protects non-human primates against a lethal systemic challenge of
ZEBOV, and induces cellular and humoral immune responses. We demonstrated that ZEBOVGP-specific T-cell and humoral
responses induced in the IN and OR groups, following an immunization and challenge, produced the most IFN-c and IL-2
secreting cells, and long term memory responses.
Conclusions/Significance: We have shown conclusively that mucosal immunization can protect from systemic ZEBOV
challenge and that mucosal delivery, particularly IN immunization, seems to be more potent than IM injection in the
immune parameters we have tested. Mucosal immunization would be a huge benefit in any emergency mass vaccination
campaign during a natural outbreak, or following intentional release, or for mucosal immunization of great apes in the wild.
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Introduction
Ebola virus (EBOV) and Marburg virus (MARV) are members
of the Filoviridae family causing a lethal viral haemorrhagic fever
(HF). Zaire ebolavirus (ZEBOV), is the most virulent species in the
Ebola genus with human case fatality rates of over 80%, [1–5].
Sporadic outbreaks of ZEBOV have occurred in Central Africa
since 1976 causing more than 1,800 human cases, as well as
epidemics among chimpanzees and great apes [6–9]. Populations
of wild apes in Central Africa have been decimated and there is a
significant risk that these populations could become extinct
because of ongoing outbreaks [7]. Importantly in the bordering
region between Gabon and the Republic of Congo, human
outbreaks have been shown to correspond to outbreaks in great
apes, and so preventing disease in these animals could potentially
prevent many human cases.
Experimental infections of non-human primates (NHPs) with
ZEBOV by intramuscular injection or mucosal exposure results in
a disease with symptomology similar to humans [10–12].
Transmission of ZEBOV is generally through exposure to infected
bodily fluids via either breaks and abrasions of the skin, or through
mucosal surfaces. It is currently unknown which plays a more
prominent role in the spread of disease. However, infection can
occur via aerosol administration [13]. In addition, there is
evidence that ZEBOV can be transmitted between experimentally
inoculated monkeys and naı ¨ve controls probably by virus-laden
droplets secreted or excreted leading to mucosal infection [14]. For
this reason there is concern of EBOV being incorporated into a
biological weapon. In addition, research was conducted into the
use of weaponized MARV with the most likely means of dispersal
through aerosol generation [15]. The severity and high fatality of
the disease, in addition to the possibility of EBOV or MARV to be
used as a bioterrorist weapon has necessitated the research and
development of vaccines for both EBOV and MARV. Currently
there is no preventative vaccine or post-exposure treatment option
approved for human or animal use.
Earlyattemptsatcreatingavaccineincludedc-irradiated MARV
[16] or ZEBOV [10]; or formalin-inactivated ZEBOV [17]. These
vaccines were able to provide protection in guinea pigs, but in the
NHP model the vaccines failed to protect. Recent attempts focusing
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5547on DNA and viral based vaccines, or virus like particles (VLP) have
been more promising. These newer vaccines are more effective in
several animal models however, to date only five EBOV vaccine
platforms have demonstrated over 80% efficacy in the more
stringent NHP model [18–26]. Previously, we described the
generation and use of live attenuated recombinant Vesicular
Stomatitis Virus (VSV) with the VSV glycoprotein replaced by
the glycoprotein of ZEBOV (VSVDG/ZEBOVGP) or MARV
(VSVDG/MARVGP) [27]. Furthermore, we demonstrated that
these live attenuated recombinant VSV vaccines completely protect
NHPs against lethal challenge with the corresponding filoviruses by
intramuscular injection (IM) [25,26,28]. In this study we are
investigating for the first time the protection provided by intranasal
(IN) or oral (OR) immunization with the VSV-based vaccines
against the standard systemic IM challenge with ZEBOV in NHPs.
We investigated the humoral and cellular immune responses
following vaccination as well as the long term memory B and T
cell immune responses post-challenge.
Results
Clinical Observations
We used 12 cynomolgus macaques, of which 10 were
immunized with VSVDG/ZEBOVGP either orally (OR; n=4),
intranasally (IN; n=4) or intramuscularly (IM; n=2). The
remaining 2 control animals were vaccinated intramuscularly
with VSVDG/MARVGP. VSVDG/MARVGP does not provide
any heterologous protection against ZEBOV, therefore these
NHPs succumb to ZEBOV infection. All animals were challenged
with 1000 PFU of ZEBOV 28 days later, and monitored daily for
clinical symptoms. An IM challenge was chosen as we have
previously demonstrated that it produces a rapid and lethal
ZEBOV HF [25]. An aerosol mucosal delivery mechanism was
not employed as the disease course progressed more slowly, and
we wished to test the vaccine against the most severe disease [13].
In addition, we have already demonstrated that the VSVDG/
ZEBOVGP vaccine fully protects against an aerosolized lethal
dose of ZEBOV [13]. In this current study, all of the VSVDG/
ZEBOVGP immunized animals were protected from the high
dose challenge and showed no evidence of clinical illness after
vaccination or ZEBOV challenge. However, the control animals
demonstrated typical symptoms associated with ZEBOV HF, such
as fever, macular rashes, lethargy, unresponsiveness and were
euthanized on day 6 (Figure 1). We performed haematology
analysis at each examination date, and other than increases in the
platelet-crit in the OR and IN groups post-challenge, we saw no
significant changes in any NHPs post-immunization or in the
VSVDG/ZEBOVGP immunized NHPs post-challenge (Table 1).
Figure 1. Survival of vaccinated cynomolgus macaques. A) Flow chart of experimental design. Arrows indicate vaccination and challenge date.
Tick marks indicate sampling days. B) Kaplan-Meier survival curve for cynomolgus macaques immunized by different routes and challenged with Zaire
ebolavirus. Cynomolgus macaques were immunized orally (OR; n=4), intranasally (IN; n=4) or intramuscularly (IM; n=2) with 2610
7 PFU of VSVDG/
ZEBOVGP, or injected intramuscularly with VSVDG/MARVGP (control; n=2). All animals were challenged 28 days later with 1000 PFU ZEBOV. The
animals were scored daily for fever, macular rashes, lethargy, and unresponsiveness.
doi:10.1371/journal.pone.0005547.g001
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was difficult to determine any significance within or between
groups. However, there was a trend towards decreased lympho-
cytes and platelets that does correspond to previous reports.
Evaluation of the antibody response
To characterize the humoral immune response, a virus like
particle (VLP) based ELISA was used to determine the levels of
ZEBOVGP-specific antibodies. The VSVDG/MARVGP immu-
nized animals never developed a detectable antibody response to
ZEBOVGP. In contrast, potent antibody responses were detected
in all VSVDG/ZEBOVGP immunized animals independent of
immunization route (Figure 2). Between days 14 and 21 post-
vaccination, all VSVDG/ZEBOVGP immunized NHPs devel-
oped high levels of IgA (IM=1:600; OR=1:2,900; IN=1:4,100),
IgM (IM=1:3,400; OR=1:6,000; IN=1:8,000), and IgG
(IM=1:6,400; OR=1:7,200; IN=1:57,600) against ZEBOVGP.
After challenge the IgM titres did not exceed the post-vaccination
levels, however, IgG and IgA antibody titres were significantly
increased peaking 14 days post-challenge then slowly decreasing
before maintaining a relatively high antibody titre up to 9 months.
Overall in the post-vaccination response, the IgM titres ranked
IN>OR.IM, with an IN titre 2.4 times higher than IM, while
IgA and IgG responses ranked IN.OR.IM (IN 6.8 fold .IM)
and IN.OR>IM (IN 9.0 fold .IM), respectively.
In order to determine the level of neutralizing antibodies (NAb)
present in the sera 21 days post-vaccination, a ZEBOV-GFP
neutralization assay was performed (Figure 3). The ZEBOV-GFP
virus contains the GFP between the NP and VP35 gene [29].
Although the ZEBOV-GFP virus is slightly attenuated in in vivo
NHP studies, the growth kinetics in the Vero E6 cell line is
virtually indistinguishable from the wild type ZEBOV, suggesting
similar levels of infectivity [29,30] The IM immunization
produced low but detectable levels of NAb (Figure 3a). In
comparison, 3/4 NHPs in the OR group (Figure 3b) demonstrated
a 50% reduction in ZEBOV-GFP positive cells at a titre of 1:40
(mean=66.7%, range:42.3–81.1%). One of the OR immunized
NHPs had a 55.5% reduction at the 1:320 dilution. Similarly, the
IN route (Figure 3c) resulted in a reduction of ZEBOV GFP
positive cells at the 1:40 dilution (mean=51.4%, range:39.1–
74.8%). Similar results were obtained using the standard plaque
neutralization assay (data not shown). Overall, while the OR and
IN routes produced ZEBOVGP-specific Nabs, the NAb titres are
relatively low, with the OR route producing the highest titres post-
vaccination
Evaluation of the cellular immune response
To evaluate the ZEBOVGP-specific effector cellular immune
responses, IL-2 and IFN-c ELISPOT assays were conducted to
determine the number of IL-2 and IFN-c secreting lymphocytes
Table 1. Blood Hematology Results for Cynomolgus Monkeys after vaccination and challenge with Ebola Virus.
Parameter VSVG/ZEBOVGP Controls
OR IN IM VSVG/MARVGP
Post Vac Post Chall Post Vac Post Chall Post Vac Post Chall Post Vac Post Chall
WBC NC NC NC NC NC NC NC NC
% Lymphocytes NC NC NC NC NC NC q day 10* Q day 3*
% Monocytes q day 3 (2/4)* NC NC NC NC NC q day 3 & 6* NC
%Neutrophils NC NC NC NC NC NC NC NC
%Eosinophils NC NC NC NC NC NC NC NC
%Basophils NC NC NC NC NC NC NC NC
HCT NC NC NC NC NC NC NC NC
RBC NC NC NC NC NC NC NC NC
HGB NC NC NC NC NC NC NC NC
Reticulocytes NC NC NC NC NC NC NC NC
% Reticulocytes NC NC NC NC NC NC NC NC
MCV NC NC NC NC NC NC NC NC
% RDW NC NC NC NC NC NC NC NC
MCHC NC NC NC NC NC NC NC NC
MCH NC NC NC NC NC NC NC NC
Platelets NC NC NC NC NC NC NC NC
MPV NC NC NC NC NC NC NC NC
PCT NC q day 6–26 (3/4)* NC q day 10,14,19 (3/4)* NC NC NC NC
% PDW NC NC NC NC NC NC NC
Pre-vaccination test results for each animal (n=12) were used to establish an average for each parameter. Post-vaccination and -challenge values were compared to the
pre-vaccination average. Significant changes in comparison to this average are indicated (*). When values for each animal were compared to its’ own pre-vaccination
values, no changes (NC) were observed in any of the parameters.
HCT=hematocrit, RBC=red blood cells, HGB=hemaglobin, MCV=mean corpuscular volume, % RDW=red cell distribution width, MCHC=mean corpuscular
hemoglobin concentration, MCH=mean corpuscular hemoglobin, MPV=mean platelet volume, PCT=platelet-crit, % PDW=platelet distribution width. Post Vac=post
vaccination, Post Chall=post challenge, OR=oral, IN=intranasal, IM=intramuscular.
doi:10.1371/journal.pone.0005547.t001
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in the IM, OR, and IN immunization routes. A ZEBOV VLP ELISA
was utilized to determine the ZEBOV-specific IgA (a), IgG (b), IgM (c)
titres in post-vaccination and post-challenge sera from cynomolgus
macaques immunized either orally (OR; n=4), intranasally (IN; n=4) or
intramuscularly (IM; n=2). Titres are presented as endpoint dilutions of
the average value per group. Table (d) illustrates fold increases in peak
titres post-challenge compared to post-vaccination for IgA and IgG. IgM
is not shown as there were no increases post-challenge.
doi:10.1371/journal.pone.0005547.g002
Figure 3. Neutralizing antibodies generated by the various
immunization routes. ZEBOV GP-specific neutralizing antibodies in
the sera from NHPs vaccinated either (A) intramuscularly (IM), (B) orally
(OR), or (C) intranasally (IN), were investigated for their ability to inhibit
infection by ZEBOV-GFP. NHP sera from days 0 and 21 post-vaccination
were incubated for 1 hour with ZEBOV-GFP before being added to a
monolayer of Vero cells. The positive control was ZEBOV-GFP in DMEM
without sera. The level of GFP fluorescence of ZEBOV-GFP infected cells
was determined by flow cytometry. The percent reduction of infection
by ZEBOV-GFP was calculated as follows: % ZEBOV-GFP reduc-
tion=(12(Test samples/Positive control))6100). The day 21 results for
each NHP are displayed and have been normalized by subtracting each
NHP’s day 0 results from the day 21 results. The numbers in the legend
represent the dilution of the NHP sera that was added to ZEBOV-GFP.
doi:10.1371/journal.pone.0005547.g003
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cells. Prior to challenge on days 10 to 14 post-vaccination there
was a detectable ZEBOVGP-specific IFN-c response in all
immunized animals (Figure 4a). The IM route was the most
potent, inducing approximately 2 fold more IFN-c secreting cells
than OR (p,0.001) or IN (p=0.043) routes. However, post-
challenge a strong secondary IFN-c response was induced in all
VSVDG/ZEBOVGP immunized animals with the IM route
producing the most IFN-c cells at day 6 but by day 10 was
overtaken by a stronger response in the OR group. The IFN-c in
the IN group rose steadily, peaking at day 26 post-challenge with
4.3 and 2 fold more ZEBOVGP specific IFN-c secreting cells than
the IM (p=0.003) and OR (p=0.075) group, respectively. All
three routes produced strong ZEBOVGP-specific IFN-c respons-
es, with the IM route dominant early after challenge but surpassed
by the OR and IN routes at later time points.
Another T-cell cytokine, IL-2, plays a key role during infection
by inducing proliferation/activation of CD4
+ and CD8
+ T cells,
potentiates the cytotoxicity of CD8
+ T lymphocytes and Natural
Killer (NK) cells, and stimulates B lymphocyte function. Post-
vaccination, the IM group had more ZEBOVGP-specific IL-2
secreting cells than either of the mucosally immunized groups
(Figure 4b). This difference was significant for the IN route on day
10 (p,0.001) and 14 (p=0.022). Post-challenge the IM route
continued to dominate early after challenge peaking on day 10.
This difference shows a trend when compared to the IN group
(p=0.067) and is significant when compared to the OR group
(p,0.001). Additionally, the IN group had more IL-2 producing
Figure 4. PBMCs from immunized animals produce IFN-c or IL-2 in response to ZEBOVGP peptides. ZEBOVGP-specific IFN-c or IL-2
secreting cells from PBMCs were detected by either an (A) IFN-c or (B) IL-2 ELISPOT assay. PBMCs were obtained from cynomolgus macaques
immunized with VSVDG/ZEBOVGP either orally (OR; n=4), intranasally (IN; n=4), or intramuscularly (IM; n=2). The control NHPs (n=2) were
immunized IM with the heterologous VSVDG/MARVGP. PBMCs were incubated with 1.5 mg/ml of peptides spanning the entire ZEBOV glycoprotein.
Bars represent the average number of ZEBOVGP-specific IFN-c or IL-2 secreting cells detected in each immunized group.
doi:10.1371/journal.pone.0005547.g004
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day 26 post-challenge all three routes continued to produce a
ZEBOVGP-specific IL-2 response, however the IN group
response was strongest with a ranking of IN.IM>OR (IN vs.
IM p=0.051; IM vs. OR p=0.838). At day 26 post-challenge the
IN group had the most potent IFN-c and IL-2 responses, as well as
the highest IgA and IgG antibody titre, indicating this immuni-
zation route, followed by a ZEBOV challenge, results in the
development of potent and sustained effector responses.
Absolute white blood cell counts following ZEBOV
challenge
In immunized animals a secondary immune response should
occur upon ZEBOV challenge resulting in a rapid amplification of
lymphocytes. However, previous reports on ZEBOV infections in
unvaccinated animals demonstrate a decrease in lymphocytes
possibly due to apoptosis [30–32]. In order to compare the
changes in cell numbers between the immunization routes, and
also confirm that lymphocytes were not lost in vaccinated animals
following ZEBOV challenge, absolute lymphocyte numbers for
CD3
+, CD4
+, and CD8
+ (CD3
+4
2) T cell populations were
determined by flow cytometry (Figure 5). As expected, in the
VSVDG/MARVGP (control) vaccinated animals who are not
protected from ZEBOV, the lymphocyte numbers decreased 28–
57% (Figure 5a: CD3
+:day 3 Q0.586, p=0.001; day 6 Q0.726,
p=0.015. Figure 5b:CD4
+:day 3 Q0.586, p=0.003; day 6
Q0.436, p=0.002. Figure 5c:CD8
+:day 3 Q0.576, p=0.003,
day 6 q1.046, p=0.642) on days 3–6 compared to day 0 post-
challenge data. In contrast, there was no decrease in the
lymphocyte populations for any of the VSVDG/ZEBOVGP
vaccinated NHPs (Figures 5a–c). Comparison within VSVDG/
ZEBOVGP inoculation routes demonstrated no significant
changes from day 0 in either the IM or IN groups, although
numbers of both CD4
+ (Figure 5b) and CD 8
+ (Figure 5c) T cells
did increase on day 3 post-challenge in the IN group (CD4
+: day 3
IN q1.226, p=0.433; CD8
+: day 3 IN q1.396, p=0.053). The
most substantial increases in total CD3
+, CD4
+, and CD8
+
numbers were on day 3 (Figure 5a:CD3
+: day 3 q1.686,
p=0.032; Figure 5b:CD4
+: day 3 q1.566, p=0.093;
Figure 5c:CD8
+: day 3 q1.806, p=0.025) in the OR group,
that then returned to normal levels by day 6. VSVDG/
ZEBOVGP vaccination prevented the loss of lymphocytes seen
in non-protected NHPs. In fact the OR and IN routes showed
increased numbers of lymphocytes on day 3 post-challenge
probably indicating a proliferation of ZEBOVGP-specific T-cells.
As antigen presenting cells, the macrophages have a major role
in the initiation of the immune response to foreign antigens.
However, they are also the primary cells infected by ZEBOV early
during infection [33,34]. Therefore, the number of CD14
+
macrophage/monocytes was examined post-challenge (Figure 5d).
The number of CD14
+ cells increased 2.26(p=0.190) on day 3 in
the control group, but the numbers were greater in the VSVDG/
Figure 5. Absolute white blood cell numbers do not decrease in immunized animals after Zaire ebolavirus challenge. Whole blood
from cynomolgus macaques immunized either orally (OR; n=4), intranasally (IN; n=4) or intramuscularly (IM; n=2) was stained for lympocytes (CD3
+,
CD4
+, CD8
+), monocytes (CD14
+). Control animals (n=2) received non protective VSVDG/MARVGP. The absolute numbers in blood was determined
for the each of the monkeys by flow cytometry on days 0, 3 and 6 post-challenge with ZEBOV. The average for each inoculation route is represented.
doi:10.1371/journal.pone.0005547.g005
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5547ZEBOVGP vaccinated groups with the IM route showing the
most significant increases (IM q10.96, p=0.001; OR q2.86,
p=0.062; IN q4.96, p=0.009).
ZEBOVGP Specific Memory Responses
In order to determine the long term immune response after
challenge, ZEBOVGP-specific CD4
+ (Figure 6a) and CD8
+
(Figure 6b) memory T lymphocytes were examined for their
ability to proliferate (CFSE
2) or produce IFN-c in response to
ZEBOVGP peptides at 6 months post-vaccination. The T
lymphocyte marker CD45RA was used to determine the memory
population (CD45RA2), and the naı ¨ve plus effector populations
(CD45RA+). In the IM immunized group, there was a very low
level of proliferation in the CD8+ memory population accompa-
nied by low levels of IFN-c production in the naı ¨ve/effector CD8+
populations, as well as the CD4+ memory population. In
comparison, the OR and IN immunized groups saw higher levels
of proliferation and IFN-c production in their CD4
+ and CD8
+
memory cells. The memory cells in both the OR and IN groups
proliferated equally well however the OR group had a higher
percentage of memory cells producing IFN-c than the IN group.
The CD45RA
+ naı ¨ve/effector populations also demonstrated low
levels of proliferation as well as produced IFN-c in response to the
ZEBOVGP peptides in the OR and IN groups. This is presumed
to be primarily due to the effector population and not the naı ¨ve
cells. Overall, the ZEBOVGP-specific memory responses that
occur as a result of vaccination followed by a ZEBOV challenge
persist for at least 6 months indicating that long term immunity is
possible in filovirus infections. The fact that the memory
populations in OR and IN inoculation routes demonstrate the
greatest potential for proliferation and IFN-c production post-
challenge suggests that different routes of immunization prime
different memory cell populations.
Discussion
In this study we have completed the only long term immune
response study, and the most extensive investigation of the T-cell
Figure 6. ZEBOVGP-specific CD4
+ and CD8
+ functional memory responses in PBMCs. Flow cytometry was utilized to evaluate the long
term CD4+ (A) and CD8+ (B) ZEBOVGP-specific functional memory responses of freshly isolated PBMCs incubated with media or ZEBOVGP peptides at
6 months post-vaccination. The average for each inoculation route (IM=intramuscular n=2, OR=orally n=4, IN=intranasally n=4) is represented.
The CD45RA
2 population denotes the memory lymphocytes, while CD45RA+ represents the naı ¨ve and effector lymphocytes. The IFN-c response was
evaluated after 3 days by intracellular cytokine staining. The background from the media sample was subtracted from the peptide stimulated sample,
and the results are shown for each monkey with the average for each group being represented with a bar. The ability of the PBMCs to proliferate in
response to the GP peptide was determined by staining the PBMCs with CFSE and then looking for loss of CFSE 6 days later as a measure of
proliferation. The percent of CFSE
2 cells for each memory population is shown for each monkey after subtracting the media sample, and the average
for each group is represented by a bar.
doi:10.1371/journal.pone.0005547.g006
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This data forms a foundation for future critical studies on the
immune correlates of protection, the potential for rapid mass
vaccination programs in humans, and the immunization of
endangered great ape populations in Africa.
We demonstrated previously that a single IM dose of VSVDG/
ZEBOVGP protects cynomolgus macaques from a high dose
challenge with ZEBOV [25]. In this study, we explored potential
routes of immunization to compare the protection conferred as
well as the immune response each route would elicit. All
immunization routes were equivalently efficacious as no NHPs
died or displayed symptoms of HF. In all cases both ZEBOVGP-
specific humoral and cell mediated immune responses (CMIR)
were generated, although some routes generated more potent
humoral responses. All animals demonstrated a high IgM response
post-vaccination, which was not exceeded following challenge.
This response is normal since IgM is produced upon initial
exposure to a new antigen during the primary but not the
secondary immune response. In general the post-vaccination IgM
and IgA titres were the highest in the IN group followed closely by
the OR group, but 2.4 and 6.8 fold lower, respectively, in the IM
route. This suggests that IN immunization was effective in eliciting
not only a primary immune response but also IgA antibodies
important for mucosal immunity. Importantly, no adverse effects
were seen in any of the immunized animals.
The most crucial immunoglobulin is IgG since it provides the
majority of the systemic antibody, which is important for a
haematological infection of ZEBOV. Once again the IN route was
most effective with post-vaccination titres 8–9 fold higher than with
OR and IMroutes. With ZEBOV challenge, the secondaryimmune
response IgG titres increased 43, 16 and 2 fold for OR, IM and IN,
respectively. Although IN titres only increased 2 fold, the final titres
weresimilar tothe OR route asthe INpre-challenge titreswerehigh
initially, and the OR immunized animals had a very strong
secondary IgG immune response after challenge. Very significantly
the IM route consistently resultedinlowerIgG titres beforeand after
challenge when compared to the mucosally immunized animals.
However, the IM animals all survived and this may indicate a
minimum threshold of antibody required for protection, with all
three routes achieving this minimum. In contrast to the total IgG
titres, the NAb titres were systemically very low (titres=1:40 to
1:320) and seem unlikelyto be important asa protective mechanism,
which is consistent with previous reports. In murine studies and
other NHP studies, anti-ZEBOV NAb were low or absent yet the
animals were resistant to a ZEBOV challenge [35–37].
The CMIR is a vital protective mechanism against viral
pathogens and in this study was induced by all immunization
routes. ZEBOV infections result in the loss of peripheral blood
lymphocytes, presumably due to apoptosis [30–32,38]. In this
study, absolute lymphocyte counts rather than percentages were
used to determine whether the VSVDG/ZEBOVGP vaccine was
able to prevent their decline. This is very important since changes
in percentages can be caused by increases or losses in cell
populations other than the one under observation. Absolute counts
in contrast measure a true value for the number of circulating cells
under investigation and other population changes do not effect the
measurement. While the controls demonstrated the typical loss in
lymphocytes, after challenge, all vaccination routes displayed a
relatively stable or mild increase of CD3
+, CD4
+ and CD8
+
numbers. An increase in lymphocyte numbers is typical of the
expansion seen during a secondary immune response, and was
most pronounced for the OR administration.
Further evidence to support the induction of CMIR is the
production of IFN-c and IL-2 cytokines measured by ELISPOT.
Previous studies have investigated the production of TNFa by T
cells rather than IL-2 however, TNFa does not have a specific role
in the induction or maintenance of the CMIR and was therefore
not included in this study. IFN-c secretion by T lymphocytes,
NKs, and dendritic cells, occurs early in the immune response to a
pathogen, and promotes the activation of antigen presenting cells
as well as the induction of a Th1 response. IL-2 which is produced
by T lymphocytes during an immune response, stimulates the
growth, differentiation and survival of antigen-specific cytotoxic
cells. All three routes induced the production of both IL-2 and
IFN-c. Post-vaccination and very early post-challenge the IM
route induced the most IFN-c and IL-2 secreting cells. However,
cytokine production in the OR and IN routes increased steadily
post-challenge and by day 26 post-challenge the OR and IN
cytokine secreting cells surpassed the IM group. The production of
IFN-c post-vaccination contrasts a previous study were we had
demonstrated that IFN-c was not produced in peripheral blood
mononuclear cells (PBMCs) post-vaccination [25]. The discrep-
ancy could be due to the different assays and tissues used, as
intracellular cytokine staining of PBMCs by flow cytometry was
performed in the earlier study versus the ELISPOT assay on the
peripheral blood cells in this paper. Overall, in this paper, the
strong production of IL-2 and IFN-c by IM injection early on
suggests the ability to induce a strong Th1 CMIR.
The induction of long term immunity is a key requirement of
any vaccine. In this study we examined the immune response
induced by the vaccines up to 28 days, as well as the long term
immunity that occurred after vaccination plus challenge. The
immune responses directly attributable to the vaccine demonstrate
that the OR and IN vaccination produce stronger humoral
responses while the IM route provides a stronger CMIR. After
challenge the strength, type and duration of the immune responses
were also measured. The ZEBOVGP-specific T lymphocyte
memory response and antibody titre was examined at 6 and 9
months post-vaccination, respectively. The OR and IN adminis-
tration produced long lasting CD4
+ and CD8
+ memory
lymphocytes that were able to proliferate and produce IFN-c in
response to ZEBOVGP peptides. On the other hand the IgA and
IgG serum titres were high for all three routes with a ranking of
IN.OR.IM. Based on this data it suggests that different routes of
immunization prime the memory responses differently. These
differences are reflected in the memory responses seen after
challenge in regards to the strength and type of response. The IM
route is more likely to produce a strong Th1 CMIR while the IN
route induced a predominantly Th1 humoral response. The
potent CMIR seen in the IM group may be a product of the high
IFN-c and IL-2 production detected post-vaccination, and early
on post-challenge. IFN-c has immunoregulatory activities during
an immune response to viral pathogens, and in addition it has
antiviral effects that may inhibit early viral replication and thereby
slow the infection [39]. Although the memory responses elicited at
6 and 9 months do not represent the effectiveness of the vaccine
alone, this measurement indicates the route of immunization has
an impact on the strength and type of immune response that is
initiated upon a subsequent infection. In addition it demonstrates
that long term protection to filoviruses is achievable, and provides
us with clues as to the correlates of immune protection.
The immune correlates of protection have not been defined for
the protection of NHPs against filoviruses. Previously, we
demonstrated an 80% survival in mouse adapted ZEBOV (MA-
ZEBOV) infected mice that had received VSVDG/ZEBOVGP
immune sera, indicating that the humoral response is partially
responsible for protection [40]. NAb titres in vaccinated animals,
or humans that have survived EBOV infections have consistently
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response appears to be the mechanism involved in the humoral
response to filovirus infections. In addition, all mice immunized
with VSVDG/ZEBOVGP survived challenge with MA-EBOV
even when depleted of CD8
+ lymphocytes, suggesting that the
cytotoxic T lymphocyte response may not be required [40]. As
further confirmation, PBMCs from NHPs that had been
immunized with an EBOV GP plus NP DNA prime then
Adenovirus ZEBOV GP boost were examined for their ability to
proliferate to ZEBOV peptides. When the CD4
+ population had
been depleted the ability to proliferate in response to the peptides
was reduced to background levels, but when the CD8
+ population
was depleted there was no drop in proliferation [22].
In our system, total Ab response, and the pre-challenge IgG
titres achieved from all routes of immunization with the VSVDG/
ZEBOVGP vaccine were high (1:6,400 to 1:57,600). Although
there is no evidence for the importance of IgA, it is vital for
mucosal immunity especially in the event of an aerosol delivery of
ZEBOV [43]. All routes were able to produce high IgA titres
although the IN and OR delivery was most effective. In addition,
the OR route was able to induce a detectable CD4
+ CMIR which
also appears to be vital to survival. Development of a vaccine for
OR or IN delivery would be desirable because they can be self
administered significantly reducing the requirement for trained
personnel especially in areas where the virus is endemic; they
stimulate mucosal immune responses, which play an essential role
in protecting the lungs from aerosol exposure; and they are more
accepted by patients as there is no needle.
We have shown conclusively that mucosal delivery of the vaccine
can protect from IM systemic challenge and very surprisingly
mucosal delivery particularly IN immunization seems to be more
potent than IM injection in many immune parameters. Mucosal
immunization would be huge benefit in any emergency mass
vaccination campaign for natural outbreaks or following intentional
release. Furthermore, mucosal immunization may be of great
significance if immunization of great apes is attempted in the wild.
Materials and Methods
Ethics Statement
Animal studies were performed in biosafety level 4 biocontain-
ment at Public Health Agency of Canada and approved by the
Canadian Science Centre for Human and Animal Health Animal
Care Committee following the guidelines of the Canadian Council
on Animal Care. Animals were acclimatized for 14 days prior to
infection. Animals were fed and monitored twice daily (pre- and
post-infection) and fed commercial monkey chow, treats and fruit.
Husbandry enrichment consisted of commercial toys and visual
stimulation.
Vaccine vectors, viruses, and peptides
The recombinant VSVDG/ZEBOVGP and VSVDG/
MARVGP vaccine expressing the glycoproteins of ZEBOV (strain
Mayinga) or Lake victoria marburgvirus (MARV) (strain Musoke) were
generated using VSV (Indiana serotype) as described previously
[27,44]. The ZEBOV (strain Kikwit) challenge virus was passaged
in Vero E6 cells prior to challenge, as described previously [25,45].
A ZEBOVGP1,2 peptide pool consisting of 15mers with 11 amino
acid overlaps (Sigma-Genosys) spanning the entire 676 amino
acids of the ZEBOV, strain Mayinga 1976 GP was used.
Animals
Twelve 5 to 19 year old healthy cynomologus macaques (macaca
fascicularis) were from a Health Canada non-human primate
colony (Health Canada Animal Resources Division, Tunney’s
Pasture, Ottawa, Ontario). Animal studies were performed in
biosafety level 4 biocontainment at Public Health Agency of
Canada and approved by the Canadian Science Centre for
Human and Animal Health Animal Care Committee following
the guidelines of the Canadian Council on Animal Care. Animals
were acclimatized for 14 days prior to infection. Animals were fed
and monitored twice daily (pre- and post-infection) and fed
commercial monkey chow, treats and fruit. Husbandry enrich-
ment consisted of commercial toys and visual stimulation.
Vaccination and Challenge Experiment
Twelve filovirus naı ¨ve cynomolgus monkeys randomized into
four groups received 2 ml of 1610
7 PFU/ml of vaccine in
Dulbecco’s modified Eagle’s medium (DMEM). Animals in the
three experimental groups were vaccinated with either: 1) 2 ml
orally (OR) (n=4); 2) 1 ml dripped into each nostril, intranasally
(IN) (n=4); or 3) 1 ml each into two sites intramuscularly (IM)
(n=2). The two controls were injected intramuscularly with 2 ml
of 1610
7 PFU/ml of VSVDG/MARVGP. All animals were
challenged intramuscularly 28 days later with 1,000 PFU of
ZEBOV (strain kikwit).
Routine examination was conducted on 0, 2, 4, 6, 10, 14 and 21
days post-vaccination, then 0, 3, 6, 10, 14, 19, 26 days, 6 and 9
months after the ZEBOV challenge. For the examinations animals
were anaesthetized by intramuscular injection with 10 mg/kg of
ketaset (Ayerst). Examinations included haematological analysis,
monitoring temperature (rectal), respiration rate, lymph nodes,
weight, hydration, discharges and mucous membranes. Also,
swabs (throat, oral, nasal, rectal, vaginal) and blood samples were
collected (4 ml from femoral vein, 1 ml in EDTA vacutainer tube;
3 ml in serum separator vacutainer tube). Cynomolgus monkey
PBMCs were isolated using BD CPT sodium citrate Vacutainers
(Becton Dickinson) as per manufacturer’s protocol.
ELISA
Generation of ZEBOV VLPs were described previously [46].
High binding polystyrene microtitre plates (Thermo) were coated
with 60 ml5mg/ml ZEBOV VLPs in phosphate buffered saline
(PBS) for I hour, 37uC. Plates were washed 46 with PBS, 0.1%
Tween-20, then blocked with 200 ml PBS-2% skim milk overnight,
4uC, before sera diluted in blocking solution (60 ml) was added, in
triplicate, for 1 hour, 37uC. After washing 46,6 0ml of detection
antibodies (Peroxidase-conjugated goat-anti-monkey, IgG, IgM, or
IgA) diluted 1:2000 in blocking solution were added for 1 hour,
37uC. After washing 46, 100 ml of substrate (ABTS+H2O2) was
added for 30 minutes at room temperature, before reading on a
Versamax microplate reader at 405 nm. A sample was positive
when the absorbance was higher than the mean plus 4 standard
deviations of the pre-vaccination negative control from each
monkey.
ZEBOV-GFP Flow Cytometric Neutralization Assay
Serum samples from days 0 and 21 post-vaccination were
assessed, in duplicate, for their ability to neutralize an infection
with ZEBOV-GFP in VeroE6 cells. Serially diluted serum samples
were incubated with an equal volume of ZEBOV-GFP [29] in
DMEM, at 37uC, 5% CO2 for 1 hr before 150 ml was added per
well of a confluent 12 well plate of VeroE6 cells (MOI=0.0005).
After 2 hours at 37uC, 5% CO2, 1 ml of DMEM, 2% fetal bovine
serym (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin was
added per well and incubated for 5 days. Cells were harvested by
removing the culture supernatant, washing with 1 ml PBS, 0.04%
EDTA, then adding 800 ml of PBS 0.04% EDTA for 5 minutes at
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overnight. The cells were acquired (10,000 events) and analyzed
with CellQuest Pro v3.3 on a Becton Dickinson FACSCalibur flow
cytometer. The percent reduction of green fluorescent protein
(GFP) fluorescence was calculated as follows: Percent GFP
reduction=(12(Test sample/Positive control))6100). The positive
control was ZEBOV-GFP and the negative control was DMEM.
The day 21 samples were normalized by subtracting each NHPs
day 0 value, therefore the limits of detection for this assay are at or
below the zero v alue of the y-axis.
ELISPOT Assay
Human IFN-c and IL-2 BD ELISPOT assays (BD Bioscience)
were performed as per manufacturer’s instructions. Briefly, 2610
5
PBMCs/well were incubated with 1.5 mg/ml of each ZE-
BOVGP1,2 peptide. Spots were quantified by an automated
ELISPOT reader (CTL, Cleveland, OH). The ELISPOT
response was considered positive when the number of specific
spots/million PBMCs was over 5 times the number detected in the
dimethylsulfoxide (DMSO) control wells.
Immunophenotyping
Whole blood (100 ml) was stained with a 100 ml mastermix of
antibodies (CD4 PerCP Cy5.5, CD14 PeCy7, CD3 APC Cy7).
CD8
+ T cells were identified as the CD3
+4
2 population. After
30 minutes, 4uC, red blood cells (RBCs) were lysed with 1.5 ml of
16FACS lysing solution (Becton Dickinson), vortexed, incubated
at room temperature for 10 minutes before centrifugation at
300 g, 10 minutes. The pellet was washed with 1 ml of wash
buffer (Dulbecco’s PBS, Invitrogen). Cells were pelleted as before
and resuspended in 900 ml of PBS, 4% PFA. Samples were
acquired (10,000 events) and analyzed on a BD LSRII flow
cytometer using FACS Diva software v5.0.2 (Becton Dickinson).
Prior to running, 100 ml of Flowcount fluorospheres (Beckman
Coulter) were added for determination of absolute counts.
T lymphocyte ZEBOVGP-specific Memory Response
For the memory response assays, 5610
5 PBMCs in 500 ml
RPMI supplemented with 10% FBS, 2 mM L-glutamine and
100 U/ml penicillin, 100 mg/ml streptomycin (RPMI-10) were
incubated with 1.5 mg/ml ZEBOVGP1,2 peptides, or media, at
37uC, 5% CO2 and measured for their ability to produce IFN-c
on day 3, or proliferate on day 6. To observe the IFN-c response
cells were washed twice with PBS, 2% FBS before blocking with
10 ul 1 mg/ml human c-globulin for 10 minutes at room
temperature. Then a 100 ml mastermix of CD45RA PECY5,
CD4 APC and CD8 PECy7 was added for 30 minutes, 4uC. Cells
were stained for IFN-c using the intracellular staining protocol of
BD’s cytofix/cytoperm Plus (with GolgiStop) Kit. Cells were then
washed and the pellet resuspended in 1 ml of PBS, 4% PFA.
Samples were acquired (100,000 events) and analyzed on the
LSRII (Becton Dickinson) using the FACS Diva software v5.0.2.
Cell proliferation on day 6 was monitored by a decrease in
carboxyfluorsecein diacetate succinimidyl ester (CFSE) staining.
On day 0 of the assay, 2610
6 PBMCs in 200 ml PBS were stained
with 200 ul of 3 mM CFSE (Invitrogen) for 8 minutes, 37uC. After
adding 400 ul of cold FBS for 1 minute, cells were washed 26
with 10 ml of PBS and resuspended at 1610
6 cells/ml in RPMI-
10. Then 500 ml of cells were combined with either media
(negative control) or 1.5 mg/ml ZEBOV GP1,2 peptides. On the
sixth day samples were subjected to the same blocking and surface
staining as the day 3 samples before washing cells, then
resuspending in 1 ml of PBS, 4% PFA. Samples were acquired
(30,000 events) and analyzed as above.
Statistics
The T test was used to determine significant responses for the
Elispot and flow cytometry data. A significant result was when
p#0.050.
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